Prevalence and impact of diabetes in patients with COVID-19 in China

Prevalence and impact of diabetes in patients with COVID-19 in China
复制标题

DOI:
10.4239/wjd.v11.i10.468
复制
发表时间:
2020-10-15
影响因子:
4.2
通讯作者:
Liu, Jue
Liu, Jue
中科院分区:
医学3区
文献类型:
--
作者:
Du, Min;Lin, Yu-Xin;Liu, Jue

文献摘要

被引文献

相似文献

2019冠状病毒病(COVID-19)是一种在全球迅速传播的新发传染病。既往研究表明,新冠肺炎合并糖尿病患者临床预后较差。目的系统评估中国COVID-19患者糖尿病患病率及其对临床结局的影响,包括ICU入院、进展为重症或死亡。方法检索2019年12月1日至2020年3月31日在PubMed、Web of Science和EMBASE上发表的研究,以确定相关的观察性研究,调查COVID-19患者中糖尿病的患病率或其对临床结果的影响。我们使用随机效应或固定效应模型来估计糖尿病的总患病率和糖尿病对预后的风险比(RR)及其95%置信区间(CI)。采用漏斗图评价发表偏倚,采用I-2统计量评价异质性。结果最终纳入23篇符合条件的文章,包括49564例COVID-19患者(1573例有糖尿病,47991例无糖尿病)。COVID-19患者中糖尿病的总患病率为10% (95%CI: 7%-15%)。在亚组分析中,与年龄较大的研究相比,年龄在50岁至50岁之间的研究中糖尿病的总患病率更高(13%;95%CI: 11%-16%)
BACKGROUND Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that has spread rapidly around the world. Previous studies have indicated that COVID-19 patients with diabetes are prone to having poor clinical outcomes.AIM To systematically evaluate the prevalence of diabetes among COVID-19 patients in China and its impact on clinical outcomes, including ICU admission, progression to severe cases, or death.METHODS We searched studies published in PubMed, Web of Science, and EMBASE from December 1, 2019 to March 31, 2020 to identify relevant observational study that investigated the prevalence of diabetes among COVID-19 patients or its impact on clinical outcomes. We used a random-effects or fixed-effects model to estimate the pooled prevalence of diabetes and risk ratio (RR) and its 95% confidence interval (CI) of diabetes on outcomes. Funnel plots were used to evaluate the publication bias and the heterogeneity was evaluated by I-2 statistic.RESULTS Twenty-three eligible articles including 49564 COVID-19 patients (1573 with and 47991 without diabetes) were finally included. The pooled prevalence of diabetes was 10% (95%CI: 7%-15%) in COVID-19 patients. In the subgroup analyses, the pooled prevalence of diabetes was higher in studies with patients aged > 50 years (13%; 95%CI: 11%-16%) than in studies with patients aged